Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $128.8 million.

  • Immunome's Net Cash Flow rose 141875.26% to $128.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.2 million, marking a year-over-year increase of 8048.12%. This contributed to the annual value of $44.7 million for FY2024, which is 4298.84% down from last year.
  • According to the latest figures from Q3 2025, Immunome's Net Cash Flow is $128.8 million, which was up 141875.26% from -$113.6 million recorded in Q2 2025.
  • Immunome's Net Cash Flow's 5-year high stood at $171.0 million during Q1 2024, with a 5-year trough of -$113.6 million in Q2 2025.
  • For the 3-year period, Immunome's Net Cash Flow averaged around $22.9 million, with its median value being $8.0 million (2023).
  • In the last 5 years, Immunome's Net Cash Flow plummeted by 163753.33% in 2024 and then skyrocketed by 141875.26% in 2025.
  • Over the past 3 years, Immunome's Net Cash Flow (Quarter) stood at $8.0 million in 2023, then crashed by 251.99% to -$12.2 million in 2024, then skyrocketed by 1153.97% to $128.8 million in 2025.
  • Its Net Cash Flow was $128.8 million in Q3 2025, compared to -$113.6 million in Q2 2025 and $114.3 million in Q1 2025.